CHANNELS

Subscribe to the InfoTech eNewsletter

infoTECH News

TMCNet:  Research and Markets: Heplisav: 1018 ISS Immunostimulatory Oligonucleotide with HBsAg (Prophylactic Hepatitis B Virus Vaccines) - Global Forecast and Market Analysis to 2022

[April 23, 2014]

Research and Markets: Heplisav: 1018 ISS Immunostimulatory Oligonucleotide with HBsAg (Prophylactic Hepatitis B Virus Vaccines) - Global Forecast and Market Analysis to 2022

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/l8hslp/heplisav) has announced the addition of the "Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022" report to their offering.

Heplisav [Hepatitis B vaccine, 1018 ISS immunostimulatory oligonucleotide with HBsAg (HBsAg-1018)] is Dynavax Technologies' adjuvanted pipeline vaccine candidate that guards adults against acute and chronic infections caused by all known strains of HBV, with a particular emphasis on protecting adults that have failed to achieve seroconversion from the currently licensed HBV vaccines. With Heplisav, Dynavax hopes to address a key clinical unmet need in the treatment landscape while simultaneously improving HBV vaccination coverage in adults.

Scope

  • Overview of Hepatitis B disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Heplisav including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Heplisav for top eight countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, UK, Japan and Canada.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Overview

3.2 Etiology and Pathophysiology

3.3 Symptoms

3.4 Prognosis (News - Alert)

4 Vaccination Recommendations and Coverage Rates

5 Competitive Assessment

5.1 Overview

5.2 Strategic Competitor Assessment

6 Opportunity and Unmet Need

6.1 Overview

6.2 Increased Vaccine Immunogenicity

6.3 Increased Vaccination Coverage Rates

6.4 Increased Patient Awareness

6.5 Improved Physician Education

6.6 More Cost-Effective Vaccines

7 Pipeline Assessment

8 Heplisav

8.1 Overview

8.2 Immunogenicity

8.3 Safety

8.4 Dosing and Formulation

8.5 Potential Clinical Positioning

8.6 Potential Commercial Positioning

8.7 Pricing and Reimbursement

8.8 SWOT Analysis

8.9 Forecast

9 Appendix

For more information visit http://www.researchandmarkets.com/research/l8hslp/heplisav


[ InfoTech Spotlight's Homepage ]


blog comments powered by Disqus

FOLLOW US

Subscribe to InfoTECH Spotlight eNews

InfoTECH Spotlight eNews delivers the latest news impacting technology in the IT industry each week. Sign up to receive FREE breaking news today!
FREE eNewsletter